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ABSTRACT
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Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction
and death. The purpose of the present study is to determine clinical characteristics associated with 28 day inhospital survival in patients with coronavirus disease 2019 (COVID-19) that received tocilizumab. This was a
retrospective observational cohort study conducted at a five hospital health system in Michigan, United States.
Adult patients with confirmed COVID-19 that were admitted to the hospital and received tocilizumab for cytokine storm from March 1, 2020 through April 3, 2020 were included. Patients were grouped into survivors and
non-survivors based on 28 day in-hospital mortality. Study day 0 was defined as the day tocilizumab was administered. Factors independently associated with in-hospital survival at 28 days after tocilizumab administration were assessed. Epidemiologic, demographic, laboratory, prognostic scores, treatment, and outcome data
were collected and analyzed. Clinical response was collected and defined as a decline of two levels on a six-point
ordinal scale of clinical status or discharged alive from the hospital. Of the 81 patients included, the median age
was 64 (58–71) years and 56 (69.1%) were male. The 28 day in-hospital mortality was 43.2%. There were 46
(56.8%) patients in the survivors and 35 (43.2%) in the non-survivors group. On study day 0 no differences were
noted in demographics, clinical characteristics, severity of illness scores, or treatments received between survivors and non-survivors. C-reactive protein was significantly higher in the non-survivors compared to survivors.
Compared to non-survivors, recipients of tocilizumab within 12 days of symptom onset was independently associated with survival (adjusted OR: 0.296, 95% CI: 0.098–0.889). SOFA score ≥8 on day 0 was independently
associated with mortality (adjusted OR: 2.842, 95% CI: 1.042–7.753). Clinical response occurred more commonly in survivors than non-survivors (80.4% vs. 5.7%; p < 0.001). Improvements in the six-point ordinal scale
and SOFA score were observed in survivors after tocilizumab. Early receipt of tocilizumab in patients with severe
COVID-19 was an independent predictor for in-hospital survival at 28 days.

1. Introduction
As of June 3, 2020 over 1.8 million cases of coronavirus disease
2019 (COVID-19) have been identified in the United States with over
105,000 deaths reported [1]. The severity of COVID-19 ranges from
asymptomatic to severe disease [2–4]. Severe disease often requires
admission to the intensive care unit (ICU) [4–6]. Mortality rates of
critically ill patients with COVID-19 range from 16 to 78% [7]. Pharmacologic treatment options have been proposed for COVID-19,

∗

including antivirals and immunomodulators [8]. Antivirals have not
demonstrated reductions in mortality to date [9–12]. Immunomodulators remain a possible therapeutic option based on the
pathophysiologic understanding of COVID-19 [13–15].
COVID-19 can progress in two overlapping phases described as an
initial viral response followed by a host inflammatory response [16].
The host response includes an unregulated pro-inflammatory cytokine
storm resulting in lung injury, development of acute respiratory distress
syndrome (ARDS), and death [16,17]. Interleukin-6 (IL-6) is theorized
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to play a significant role in the COVID-19 related cytokine storm
[13–16]. Tocilizumab, an IL-6 receptor antagonist, has garnered interest as a possible treatment option [8,14,18]. The use of IL-6 receptor
antagonists is recommended in the setting of clinical trials [19,20].
Risks of immunomodulator use include propagation of COVID-19 progression by interfering with innate antiviral immunity, development of
secondary infections, and adverse drug effects [21–24]. Given the high
mortality rates observed in severe COVID-19, clinicians have used offlabel tocilizumab and other immunomodulatory agents in practice in
select cases [25–29].
Literature to date on tocilizumab in COVID-19 has described outcomes at 14 days, predominately in those with less severe disease, and
with limited descriptions of adverse effects. The factors associated with
a beneficial response from tocilizumab are unknown. We report the
clinical characteristics associated with in-hospital survival at 28 days in
patients with COVID-19 receiving off-label tocilizumab.

cytokine storm, as described below, when assessed by the primary and
infectious disease physician.
Patients were eligible for tocilizumab if exhibiting persistent fevers
(38.0 °C for greater than 6 h), had a partial pressure of oxygen to
fraction of inspired oxygen ratio less than 200, and exhibited persistently rising inflammatory laboratory parameters (ferritin, D-dimer,
and lactate dehydrogenase (LDH)) or an elevated inflammatory laboratory parameter defined as a ferritin ≥1000 μg/L, D-dimer ≥ 5 mg/
mL, or LDH ≥ 500 U/L. An IL-6 level ≥ five times the upper limits of
normal (≤5 pg/ml) was assessed in addition to the above parameters.
Bacterial, fungal, and alternate viral infections were to be ruled out
prior to tocilizumab administration. Tocilizumab was administered as
an 8 mg/kg IV dose using actual body weight with a maximum dose of
800 mg. Doses were rounded to 400 mg, 600 mg, or 800 mg. Patients
were eligible for a second dose if persistently febrile despite treatment.
Due to medication shortages the tocilizumab dose was changed to a
fixed 400 mg IV dose for all patients on March 30, 2020.

2. Materials and methods
2.1. Study design and participants

2.3. Data collection

This was a retrospective cohort study of patients admitted to a fivehospital health system in southeast and south-central Michigan. The
study was approved by Henry Ford Health System's Institutional Review
Board (IRB #13809) with waiver of consent.
Patients hospitalized from March 1, 2020 through April 3, 2020
were eligible for inclusion if they were 18 years of age or older, had
confirmed COVID-19 infection, and received tocilizumab. Patients were
excluded if they were transferred from an out-of-system hospital, had a
positive microbiologic culture 24 h prior to or 48 h after tocilizumab
administration that was treated with an antimicrobial, were pregnant,
or incarcerated. A confirmed case of COVID-19 was defined as a patient
with positive reverse-transcriptase–polymerase-chain-reaction (RTPCR) assay for severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) in a nasopharyngeal sample tested by the Michigan Department
of Health and Human Services or the health system's centralized clinical
microbiology laboratory.
Patients were risk stratified by symptoms prior to tocilizumab administration as mild, moderate, or severe COVID-19. Patients without
hypoxia or exertional dyspnea were considered to have mild COVID-19.
Patients who presented with infiltrates on chest radiography and required supplemental oxygen by nasal cannula or high-flow nasal cannula (HFNC) were classified as having moderate COVID-19. Patients
who had respiratory failure requiring invasive mechanical ventilation
were classified as having severe COVID-19 [30]. All patients were followed for up to 28 days from the first dose of tocilizumab. Patient data
was censored on April 30, 2020.

Data was ascertained from the health system's electronic medical
record and recorded in a standardized electronic case report form.
Demographic data, information on clinical symptoms at presentation,
vital signs, laboratory tests, chest radiograph results, COVID-19 treatments received prior to tocilizumab, length of stay, and discharge disposition were collected. Baseline data was defined as information collected within 24 h from emergency department presentation. Study day
0 was defined as the first day tocilizumab was administered.
The comorbidity, age, lymphocyte, and LDH (CALL) score was calculated at baseline [31]. The score ranges from 4 to 13, with increased
values predicting higher likelihood of progressing to severe COVID-19.
The sequential organ failure assessment (SOFA) score and a six-point
ordinal scale of clinical status (as recommended by the World Health
Organization R&D Blueprint Group) were collected at baseline and after
tocilizumab administration [10,32]. The six-category scale consists of
the following categories: 1, not hospitalized; 2, hospitalized, not requiring supplemental oxygen; 3, hospitalized, requiring supplemental
oxygen; 4, hospitalized, requiring HFNC, non-invasive mechanical
ventilation, or both; 5, hospitalized, requiring invasive mechanical
ventilation, ECMO, or both; and 6, death. The American Society for
Transplantation and Cellular Therapy (ASTCT) consensus grading for
cytokine release syndrome (CRS) used for chimeric antigen receptor Tcell therapy was collected prior to tocilizumab [33]. The ASTCT
grading ranges from 1 to 5 and has three features including temperature, blood pressure, and oxygenation support to denote CRS grade.
ARDS was diagnosed and classified according to the Berlin Definition
[34]. Adverse effects observed in practice and those known to be associated with chronic tocilizumab use were collected. Infection after
tocilizumab was defined as a positive microbiologic assay that
prompted antimicrobials for the identified pathogen.

2.2. Study procedures
Hospitalized patients with COVID-19 received supportive care
comprised of supplemental oxygen, HFNC, invasive mechanical ventilation, antibiotics, vasopressors, and renal-replacement therapy, as
determined by the primary team. Patients who progressed to ARDS
were managed with lung protective ventilation strategies [19]. An institutional treatment COVID-19 guideline was developed that included
lopinavir-ritonavir with ribavirin or hydroxychloroquine monotherapy
based on disease severity. Intravenous (IV) remdesivir was available for
compassionate use or within a clinical trial. The institutional guidelines
were developed by consensus, and based on the available literature,
experience from Wuhan, China and other centers around the world
affected by COVID-19 before Michigan. On March 17, 2020 lopinavirritonavir with ribavirin was removed [9]. A short course of corticosteroids was added to the institutional guideline for patients with
moderate to severe COVID-19 on March 20, 2020 [19,30]. Tocilizumab
was used on a case-by-case basis for patients exhibiting symptoms of

2.4. Outcome measures
Characteristics of non-survivors, defined as in-hospital death within
28 days of tocilizumab administration, were compared to survivors.
Comparisons included assessment of demographics, time from symptom
onset to tocilizumab administration ≤12 days, laboratory parameters,
alternative treatments received, and prognostic scores collected [9].
Other endpoints evaluated included clinical response to tocilizumab,
defined as a decline of two levels on the six-category scale or discharged
alive from the hospital [10]. A comparison of laboratory parameters,
SOFA score, six-category scale, and severity of ARDS in survivors and
non-survivors from days 0–15 was completed. The six-category scale
was also assessed at study day 28.
2
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Table 1
Clinical characteristics and treatment prior to tocilizumab on day zero.
Characteristics

Total (n = 81)

Survivor (n = 46)

Non-Survivor (n = 35)

p-value
0.702
0.174
0.616

Demographics
Median age (IQR) - yr
Male sex – no. (%)
Race – no. (%)
African American
Caucasian
Other
Median weight (IQR) - kg
Median body mass index (IQR) - kg/m2

64 (58–71)
56 (69.1)

64 (59–70)
29 (63.0)

67 (51–72)
27 (77.1)

52 (64.2)
24 (29.6)
5 (6.2)
102.1 (88.5–117.9)
33.2 (28.8–39.1)

29 (63.0)
13 (28.3)
4 (8.7)
101.4 (89.1–117.9)
34.2 (29.2–39.3)

23 (65.7)
11 (31.4)
1 (2.9)
104.3 (87- 119.8)
31.4 (28.3–38.9)

0.853
0.341

Comorbidities – no. (%)
Asthma
Chronic obstructive pulmonary disease
Congestive heart failure
Coronary artery disease
Diabetes
End stage renal disease
Hypertension

11 (13.6)
4 (4.9)
8 (9.9)
15 (18.5)
37 (45.7)
1 (1.2)
60 (74.1)

6 (13.0)
4 (8.7)
3 (6.5)
9 (19.6)
23 (50.0)
1 (2.2)
35 (76.1)

5 (14.3)
1 (2.9)
5 (14.3)
6 (17.1)
14 (40.0)
0 (0)
25 (71.4)

1.00
0.383
0.281
0.781
0.371
1.00
0.636

Clinical characteristics
Inpatient disposition – no. (%)
General medical ward
Intensive care unit
COVID-19 classification – no. (%)
Mild
Moderate
Severe

7 (8.6)
74 (91.4)

5 (10.9)
41 (89.1)

2 (5.7)
33 (94.3)

1 (1.2)
10 (12.3)
70 (86.4)

1 (2.2)
7 (15.2)
38 (82.6)

0 (0)
3 (8.6)
32 (91.4)

Treatment prior to tocilizumab – no. (%)
Empiric antibiotics
Corticosteroids
Hydroxychloroquine
Lopinavir/ritonavir with ribavirin
Remdesivir
Prone mechanical ventilation
Neuromuscular blockade
Renal replacement therapy
Propofol sedation

58 (71.6)
57 (70.4)
74 (91.4)
4 (4.9)
2 (2.5)
22 (27.2)
14 (17.3)
1 (1.2)
50 (61.7)

35 (76.1)
31 (67.4)
42 (91.3)
2 (4.4)
0 (0)
10 (21.7)
6 (13.0)
1 (2.2)
27 (58.7)

23 (65.7)
26 (74.3)
32 (91.4)
2 (5.7)
2 (5.7)
12 (34.3)
8 (22.9)
0 (0)
23 (65.7)

0.305
0.501
1.00
1.00
0.184
0.209
0.247
1.00
0.520

10 (8–13)
60 (74.1)

9 (7–11)
38 (82.6)

11 (9–15)
22 (62.9)

62 (76.5)
19 (23.5)

38 (82.6)
8 (17.4)

24 (68.6)
11 (31.4)

0.038
0.0445
0.140

6.8 (5–7.8)
800 (400–800)

7.4 (5.5–8.0)
800 (600–800)

6.1 (4.6–7.6)
800 (400–800)

0.074
0.212

6.4 (4.4–7.8)
600 (400–800)
7.6 (5.9, 8.8)
800 (600–800)

7.6 (5.4–8.1)
700 (500–800)
7.6 (6.2, 8.8)
800 (600–800)

5.5 (4.4–6.9)
400 (400–800)
7.6 (5.1, 9.1)
800 (600–800)

0.104
0.465
0.791
0.786

22 (7.0–62)
(n = 38)
16.8 (11.2–27.2)
(n = 67)
1470 (885–2543)
(n = 71)
462 (363.5–647.8)
(n = 70)
3.1 (1.9–10.9)
(n = 58)

12 (5–32)
(n = 22)
13.8 (9.5–21.5)
(n = 37)
1066 (668–2041)
(n = 37)
431 (359–534)
(n = 37)
2.9 (1.8–9.2)
(n = 34)

47.5 (15.5–82)
(n = 16)
19.0 (14.4–32.7)
(n = 30)
1923 (1332–3000)
(n = 34)
485 (378–756)
(n = 33)
5.1 (2.3–20)
(n = 24)

0.126

9 (6–11)
5 (2–8)

8 (5–10)
4 (1–8)

9 (7–11)
5 (3–8)

1 (1.2)
3 (3.7)
7 (8.6)

1 (2.2)
2 (4.4)
5 (10.9)

0 (0)
1 (2.9)
2 (5.7)

Tocilizumab characteristics
Median days of symptoms to tocilizumab (IQR)
≤12 days – no. (%)
Number of doses – no. (%)
One
Two
First tocilizumab dose (mg)
Median mg/kg dose (IQR)
Median dose (IQR)
Second tocilizumab dose (mg)
Median mg/kg dose (IQR)
Median dose (IQR)
Median cumulative mg/kg dose (IQR)
Median cumulative dose (IQR)
Laboratory results, median (IQR)
Interleukin-6 (pg/mL)
C-reactive protein (mg/dL)
Ferritin, serum (ng/mL)
Lactate dehydrogenase, serum (units/L)
D-dimer (mg/mL)
Clinical scores
Median SOFA (IQR)
Median change in SOFA from baseline (IQR)
Six-category scale – no. (%)
2–Hospital admission, no supplemental oxygen
3–Hospital admission, supplemental oxygen
4–Hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation

0.693
0.602

0.010
0.141
0.301
0.211

0.065
0.364
0.755

(continued on next page)
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Table 1 (continued)
Characteristics

Total (n = 81)

Survivor (n = 46)

Non-Survivor (n = 35)

5–Hospital admission, requiring invasive mechanical ventilation or extracorpeal membrane
oxygenation
6–Death
Acute respiratory distress syndrome – no. (%)
Acute respiratory distress syndrome severity – no. (%)
Mild
Moderate
Severe
ASTCT cytokine release syndrome grading – no. (%)
Criteria not met
Grade 1
Grade 2
Grade 3
Grade 4

70 (86.4)

38 (82.6)

32 (91.4)

0 (0)
67 (82.7)

0 (0)
35 (76.1)

0 (0)
32 (91.4)

9 (13.4)
33 (49.3)
25 (37.3)

8 (22.9)
15 (42.9)
12 (34.3)

1 (3.3)
18 (56.3)
13 (40.6)

12 (14.8)
1 (1.2)
2 (2.5)
6 (7.4)
60 (74.1)

8 (17.4)
1 (2.2)
2 (4.4)
4 (8.7)
31 (67.4)

4 (11.4)
0 (0)
0 (0)
2 (5.7)
29 (82.9)

p-value

0.083
0.062

0.592

*IQR denotes interquartile range, COVID-19 denotes coronavirus disease 2019, SOFA denotes sequential organ failure assessment, ASTCT denotes American Society
for Transplantation and Cellular Therapy.
Table 2
Multivariate analysis of independent risk factors for in-hospital 28 day mortality.
Variable

Adjusted Odds Ratio

95% Confidence interval

p-value

Tocilizumab within ≤12 days of symptom onset
Male sex
SOFA score ≥8

0.296
2.363
2.842

0.098–0.889
0.809–6.903
1.042–7.753

0.030
0.116
0.041

The following variables were assessed for goodness of fit within the multivariate analysis and did not fit the model: age > 60, presence of acute respiratory distress
syndrome, use of prone mechanical ventilation, body mass index greater than 30, CALL score ≥7, African American, presence of infection.
*SOFA denotes sequential organ failure assessment.
Table 3
Clinical outcomes at the end of the study day 28.
Clinical endpoints
Outcomes
Clinical improvement per six-category scale with tocilizumab – no. (%)
Six-category scale by day 28 – no. (%)
1–Discharge (alive)
2–Hospital admission, no supplemental oxygen
3–Hospital admission, supplemental oxygen
4–Hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation
5–Hospital admission, requiring invasive mechanical ventilation or extracorpeal membrane
oxygenation
6–Death
Hospitalization and disposition characteristics
Mechanical ventilation at any time – no. (%)
Median days of mechanical ventilation (IQR)
Median days of intensive care unit (IQR)
Median days of hospitalization (IQR)
Hospital discharge disposition – no. (%)
Still hospitalized
Home
Long term care facility

Total (n = 81)

Survivor (n = 46)

Non-Survivor (n = 35)

p-value

39 (48.1)

37 (80.4)

2 (5.7)

32 (39.5)
2 (2.5)
4 (4.9)
0 (0)
8 (9.9)

32 (65.6)
2 (4.4)
4 (8.7)
0 (0)
8 (17.4)

0
0
0
0
0

< 0.001
< 0.001

35 (43.2)

0 (0)

35 (100)

77
10
12
18

43 (93.5)
10 (5–23)
12 (6–27)
27.5 (14–31)

34 (97.1)
9 (7–15)
11 (8–18)
14 (9–20)

14 (30.4)
18 (39.1)
14 (30.4)

0 (0)
0 (0)
0 (0)

(95.1)
(6–16)
(7–20)
(13–29)

14 (17.3)
18 (22.2)
14 (17.3)

(0)
(0)
(0)
(0)
(0)

0.630
0.157
0.181
< 0.001

*IQR denotes interquartile range.

2.5. Statistical analysis

included in a multivariate regression model that was restricted to a
subject-to-variable ratio of 10:1. Statistical analysis was performed
using IBM SPSS version 25 (Chicago, IL) and SAS 9.4 (Cary, NC).

Continuous variables were reported as median and interquartile
range (IQR) and compared using the Mann-Whitney U test or student ttest, as appropriate. Categorical data was reported as number and
percentage (no., %) and compared using the chi-squared test or Fisher's
exact test, as appropriate. No imputations were made for missing data
points. The sample size was derived from all eligible consecutive hospitalized patients during the study period. A two-sided α < 0.05 was
considered statistically significant. Bivariate and multivariate logistic
regression analysis were planned a-priori to identify independent predictors associated with 28 day in-hospital survival. Covariates in the
bivariate analysis with a p-value < 0.2 and clinical rationale were

3. Results
A total of 92 patients with an order for tocilizumab were identified.
Eleven were excluded, leaving 81 available for analysis in the study
(Supplemental Fig. 1). The median age was 64 (58–71) years and 69.1%
were male. The median time from COVID-19 symptom onset to hospital
admission was 5 (3–7) days. The 28 day in-hospital mortality was
43.2%, leaving 46 patients in the survivors and 35 in the non-survivors
group. On study day 0 patients were classified as having mild,
4
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Fig. 1. Temporal changes in laboratory parameters after tocilizumab administration. Fig. 1 shows temporal changes in C-reactive protein, serum ferritin, lactate
dehydrogenase, and D-Dimer. The n values in parenthesis represents the evaluable population in the data, if not representative of the entire cohort. Median values are
shown by the circles graphed on the line, interquartile range is denoted by the error bars above and below the circles. a p < 0.05 for non-survivors vs survivors on
study day. CRP=C-reactive protein, LDH = lactate dehydrogenase.

moderate, or severe COVID-19 in 1 (1.2%), 10 (12.3%), and 70 (86.4%)
of cases, respectively. The median SOFA score was 9 (6–11) on day 0,
and the median increase in the SOFA score from baseline was 5 (2–8).
The C-reactive protein was higher in non-survivors (13.8 [9.5–21.5] vs.
19 [14.4–32.7] mg/dL; p = 0.01).
There were no differences observed in the prevalence of comorbidities, rate of obesity, median SOFA score on day 0, or median
change in SOFA score from baseline to day 0 between survivors and
non-survivors. No other differences were noted between the survivors
and non-survivors at baseline or on day 0 (Table 1 and Supplemental
Table 1). The median days from symptom onset to tocilizumab administration was 10 (8–13) days. There was a difference in time from
symptom onset to tocilizumab administration between survivors and
non-survivors (9 [7–11] vs. 11 [9–15]; p = 0.038). There were no
differences noted in the COVID-19 treatment characteristics or prognostic scores of survivors and non-survivors (Table 1).
The single independent predictor of 28 day in-hospital survival was
receipt of tocilizumab within 12 days of symptom onset (adjusted OR:
0.296, 95% CI: 0.098–0.889). A SOFA score ≥8 was independently
associated with 28 day in-hospital mortality (adjusted OR: 2.842, 95%
CI: 1.042–7.753) (Table 2). Patients in the survivor group were more
likely to have a clinical response to tocilizumab by day 28 (80.4% vs
5.7%; p = < 0.001). The hospital length of stay was longer in the
survivors compared to non-survivors (27.5 [14–31] vs 14 [9–20];
p < 0.001). Fourteen (17.3%) patients remained hospitalized at the
end of the study (Table 3). Numerical reductions in ferritin and CRP

were observed in survivors and non-survivors after tocilizumab administration to study day 15. Lactate dehydrogenase declined in survivors from day 0–15. Significant differences were observed in CRP,
LDH, D-Dimer, and ferritin levels when comparing survivors and nonsurvivors on select study days as depicted in Fig. 1. Improvements were
observed in the six-category scale, SOFA score, and ARDS severity when
comparing the survivors to non-survivors from study day 0–15 (Fig. 2).
Twenty-nine (35.8%) patients experienced hypertriglyceridemia
with levels greater than 500 mg/dL. Of the patients that developed
hypertriglyceridemia, eight did not receive propofol. All patients with
elevated amylase and lipase levels received concurrent propofol. A total
of 18 (22.2%) patients developed an infection. The median time to
development of infection from tocilizumab was 9 (6–13) days. No difference was observed in the median time to development of infection
between survivors and non-survivors. There was a total of seventeen
(21.0%) bacterial infections and three (3.7%) fungal infections. No
differences were noted in the occurrence of adverse effects between
survivors and non-survivors (Supplemental Table 2).
4. Discussion
In this retrospective cohort study, the clinical characteristics, factors
independently associated with survival, and 28 day outcomes in patients with COVID-19 after tocilizumab administration were described.
Receipt of tocilizumab within 12 days of symptom onset in patients
with COVID-19 was the only factor independently associated with in5
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Fig. 2. Temporal changes in clinical scores after tocilizumab administration. Fig. 2 shows temporal changes in six-category score, SOFA score, ARDS severity. Median
values are shown by the circles graphed on the line, interquartile range is denoted by the error bars above and below the circles. The n values in parenthesis
represents the evaluable population in the data, if not representative of the entire cohort. For ARDS: 4 = severe, 3 = moderate, 2 = mild, 1 = invasive mechanical
ventilation without ARDS, 0 = not receiving invasive mechanical ventilation. a p < 0.05 for non-survivors vs survivors. SOFA = sequential organ failure assessment, ARDS = acute respiratory distress syndrome.

hospital survival at 28 days. A clinical response was more likely to
occur in those that survived. The association with improved survival
remained intact when adjusting for SOFA score and male sex. COVID-19
progression has been characterized by a biphasic response with the
latter phase consisting of an excessive hyper-inflammatory response
[16]. Early intervention to mitigate the cytokine storm with an immunomodulator may optimize patient outcomes. This study further
supports that intervention timing relative to disease onset is a key factor
[27].
The study population had a high likelihood for severe COVID-19
and mortality based on presenting CALL and SOFA scores [31,35]. High
rates of obesity, hypertension, and diabetes were observed in the present study relative to previous epidemiologic reports of COVID-19
[5,7]. Rates of mechanical ventilation and mortality were higher
compared to previous reports of tocilizumab use in COVID-19. Reasons
for this difference in mortality may be explained by a difference in
severity of illness, high rates of co-morbidities associated with severe
COVID-19, a longer duration of follow-up, a higher rate of invasive
mechanical ventilation, and rates of ARDS [25–28]. Mortality rates
observed in the present study are similar to those reported for critically
ill COVID-19 populations and the general ICU population with ARDS
[7,36,37].
A SOFA score of ≥8 on day 0 was independently associated with
mortality. A SOFA score of ≥3 on hospital presentation has been

described as an independent predictor for mortality in the COVID-19
population [35]. An improvement was noted in survivors for SOFA
scores and six-category scale. ARDS severity was also improved in
survivors, a finding consistent with other immunomodulatory trials
[29]. These findings are important to guide the use of off-label tocilizumab in those with cytokine storm associated with COVID-19 until
results of randomized controlled trials are available.
No standard definition for cytokine storm related to COVID-19 exists. Previous studies have defined cytokine storm associated with
COVID-19 using various threshold values for vital signs, CRP, IL-6,
ferritin, and LDH [25–27,29]. CRP is the only common diagnostic
marker amongst all published reports to date with values of 5–10 mg/
dL (10–20 times the upper limits of normal) being used to define cytokine storm. Following tocilizumab administration in the present
study, CRP was reduced in all patients, as seen in previous reports of
tocilizumab and an IL-1 receptor antagonist, anakinra [25–29]. The
ASTCT grading for CRS identified 85.2% of patients with cytokine
storm, but this may be an imperfect diagnostic tool in the setting of
COVID-19. Future research is needed to establish criteria to define cytokine storm associated with COVID-19 and identify progression of
disease from the viral phase to the hyper-inflammatory phase [16].
Recent studies have demonstrated the effectiveness of antivirals in
limiting disease severity [10,12]. A step-wise treatment approach using
antiviral and immunomodulatory agents in succession for patients with
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disease progression appears to be a viable therapeutic approach that
may warrant research.
Hypertriglyceridemia occurred frequently in the present cohort, irrespective of propofol use. Clinicians should routinely monitor triglyceride levels, markers for pancreatitis, and secondary hemophagocytic
lymphohistiocytosis (sHLH) if tocilizumab is administered. Due to the
inflammatory markers associated with sHLH, an IL-6 antagonist may
not prevent this complication, and continuous monitoring is paramount
[23]. Secondary infections were noted in 22.2% of patients, which is
higher than a previous report of 16%; however, rates in epidemiologic
reports of critically ill COVID-19 populations describe a range of
4.7–32.5% [10,28,35,38,39]. If unable to enroll patients into a clinical
trial, clinicians should consider a multidisciplinary approach to weigh
the benefits and potential risks of off-label tocilizumab for COVID-19.
This study has several limitations. The study population included is
predominately one that is critically ill with severe COVID-19, and results may not be applicable to less severe populations. This study was
conducted within a single health system, with a limited sample size, and
with no placebo comparator group. The study follow-up period was 28
days after tocilizumab administration which limits the assessment of
long term efficacy and adverse effects. However, the follow-up is longer
than what has been reported for tocilizumab and is consistent with
duration of follow-up for antiviral agents [9,10]. The health system's
COVID-19 guideline were modified during the study period, but the
treatments received in both survivors and non-survivors was consistent.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jaut.2020.102512.
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